Biology subjects

Abadie, P.

Publications and source records attributed to Abadie, P..

3 recordsLinked to original sources

bioRxiv2026

Heterogeneity of Brain Dynamics in Genetic and Psychiatric Conditions

Whether the heterogeneity of psychiatric conditions converges on shared neurophysiological alterations or translates into distinct signatures remains unclear. We assembled high-density electroencephalogram (hd-EEG) resting-state recordings from 4,812 individuals aged 5 months to 66 years across 11 psychiatric conditions, a broad spectrum of rare genetic variants, and typically developing (TD) individuals. We established normative developmental trajectories of source-space EEG across spectral organization, connectivity, and signal complexity. Psychiatric conditions showed small deviations, revealing a shared transdiagnostic profile. In contrast, single rare variants showed substantially larger, distinct and sometimes mirror-opposite signatures that collapsed toward the psychiatric profile when pooled. Autism Spectrum Disorder showed some of the smallest group-level effects yet the largest individual deviations, indicating substantial but directionally inconsistent alterations. EEG deviations followed a cortical gradient, with larger effects in sensorimotor regions. We demonstrate that sample sizes in the hundreds are required for robust associations with psychiatric diagnoses. This interactive open resource provides normative scores to benchmark future results.

neuroscience↗

bioRxiv2026

The Q1K Integrated EEG and Eye-Tracking Experimental Test Battery for Open Autism Science

The Quebec 1000 Families (Q1K) platform has been designed to recruit, phenotype, and collect biospecimens from a large cohort of families with at least one member with autism spectrum disorder or a related neurodevelopmental condition. As part of the Q1K protocol, an experimental test battery was developed and validated using simultaneous high-density electroencephalography (EEG) and eye tracking (ET). We report on the general approach and design principles, multimodal EEG/ET integration, the tasks, and their validation, providing a blueprint for implement such a project. It also describes the cohort and its methods as a reference for future studies using this dataset. By releasing openly this experimental test battery, we aim to support task standardization and multi-project data pooling in autism and related neurodevelopmental disorders.

neuroscience↗

bioRxiv2018

High-quality SNPs from genic regions highlight introgression patterns among European white oaks (Quercus petraea and Q. robur).

The Src homology-2 domain containing phosphatase SHP2 is a critical regulator of signal transduction, being implicated in cell growth and differentiation. Activating mutations cause developmental disorders and act as oncogenic drivers in hematologic cancers. SHP2 is activated by phosphopeptide binding to the N-SH2 domain, triggering the release of N-SH2 from the catalytic PTP domain. Based on early crystallographic data, it has been widely accepted that opening of the binding cleft of N-SH2 serves as the key "allosteric switch" driving SHP2 activation. To test the putative coupling between binding cleft opening and SHP2 activation as assumed by the "allosteric switch" model, we critically reviewed structural data of SHP2 and we used extensive molecular dynamics (MD) simulation and free energy calculations of isolated N-SH2 in solution, SHP2 in solution, and SHP2 in a crystal environment. Our results demonstrate that the binding cleft in N-SH2 is constitutively flexible and open in solution, and that a closed cleft found in certain structures is a consequence of crystal contacts. The degree of opening of the binding cleft has only a negligible effect on the free energy of SHP2 activation. Instead, SHP2 activation is greatly favored by the opening of the central {beta}- sheet of N-SH2. We conclude that opening of the N-SH2 binding cleft is not the key allosteric switch triggering SHP2 activation. Significance StatementSHP2 is a multi-domain protein, playing an important role in up-regulating cellular processes such as cell survival, proliferation, and programmed cell death. SHP2 mutations cause developmental disorders and were found in many cancer types, including neuroblastoma, breast cancer, and leukemia. In healthy cells, SHP2 mainly takes an autoinhibited, inactive form, and SHP2 is activated upon binding of phosphopeptides to the N-SH2 domain. For the past two decades, the widening of the binding cleft upon peptide binding has been considered as the key event driving SHP2 activation. Here, by analyzing crystallographic data and molecular simulations, we demonstrate that the binding cleft in N-SH2 is, instead, already open and accessible in solution, and its degree of opening does not influence SHP2 activation.

evolutionary biology↗